While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
[More]
Data presented at the American Urological Association Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate, results in significantly shorter hospitalization, catheterization, and recovery times for patients, while maintaining equivalent safety and efficacy.
[More]
An assistant professor at Saint Louis University's College for Public Health and Social Justice has received a $100,000, two-year grant from the Robert Wood Johnson Foundation to determine which behaviors and policies are most likely to improve the health of African-American men.
[More]
Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism.
[More]
Cancer is the No. 1 health concern among our country's middle-income Americans, according to a new study released by Washington National Institute for Wellness Solutions.
[More]
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
[More]
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, have enhanced a device they developed to identify and "grab" circulating tumor cells, or CTCs, that break away from cancers and enter the blood, often leading to the spread of cancer to other parts of the body.
[More]
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
[More]
Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
[More]
Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.
[More]
Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.
[More]
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research.
[More]
The U.S. Department of Health and Human Services, Office for Civil Rights is proud to launch the Information Is Powerful Medicine campaign.
[More]
Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients – the next question is to figure out how to match the right treatments with the right patients.
[More]
The need to add tissue preserving therapies to the prostate cancer treatment continuum was highlighted prominently at the 108th Annual Meeting of the American Urological Association, in San Diego.
[More]
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
[More]
Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.
[More]
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.
[More]
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.
[More]
Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication.
[More]